Baird Capital Sells Prescient Healthcare Group

Following the transaction, the private equity group will reinvest to hold a minority interest in the former portfolio company

LONDON, 21 January 2021 – Baird Capital announced today the sale of portfolio company Prescient Healthcare Group (“Prescient”) to Bridgepoint Development Capital (“Bridgepoint”), the international alternative asset fund management group. Following the transaction, Baird Capital will continue to hold a minority interest in Prescient. The terms of the transaction were not disclosed.

Prescient is headquartered in London and has additional offices in the U.S., India and China. The business is a global provider of pharmaceutical intelligence, insights and product strategy. Prescient helps its clients make better clinical and commercial decisions, resulting in enhanced outcomes for patients, customers and shareholders. Prescient partners with many of the world’s leading multinational pharmaceutical companies, as well as a growing number of emerging biotech and specialty pharma organisations.

Baird Capital originally invested in Prescient in 2017 and has helped the company build out its data-driven technology platform, which now provides real-time, dynamic data and insights alongside expert strategic advice to the global life sciences industry. Baird Capital has supported Prescient to further its international footprint and team.

Andrew Ferguson, Partner with Baird Capital, commented, “We invested in Prescient back in 2017 because we saw an opportunity to leverage our global resources to help an outstanding business grow even quicker and we are very pleased to have supported Prescient’s development and success over the past few years. We look forward to continuing our relationship as a minority shareholder, and we believe Prescient will continue to thrive in partnership with Bridgepoint.”

Jamie Denison-Pender, CEO of Prescient Healthcare Group, said, "It's been a pleasure working with Baird Capital, and I am delighted that they will continue as an investor in Prescient. We are proud of the way we worked to build out our capabilities over the past few years, particularly in India and the U.S., and we are well-positioned and excited for our next phase of growth." 

Baird Capital was advised by Alantra Corporate Finance and Edgemont Partners (financial) and Squires Patton Boggs (legal).

For more information on Baird Capital’s investment approach, team members, or portfolio, visit BairdCapital.com.

About Baird Capital

Baird Capital makes venture capital, growth equity and private equity investments in strategically targeted sectors around the world. Having invested in more than 320 companies over its history, Baird Capital partners with entrepreneurs and, leveraging its executive networks, strives to build exceptional companies. Baird Capital provides operational support to its portfolio companies through teams on the ground in the United States, Europe and Asia, a proactive portfolio operations team and a deep network of relationships, which together strive to deliver enhanced shareholder value. Baird Capital is the direct private investment arm of Robert W. Baird & Co. For more information, please visit BairdCapital.com.

Baird Capital Partners Europe Limited is authorised and regulated in the United Kingdom by the Financial Conduct Authority.

For additional information, contact:

Rachel Berkowitz
Baird Public Relations
rberkowitz@rwbaird.com
414-298-5101